Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Toevoegen atezolizumab bij gemetastaseerd, persisterend of gerecidiveerd cervixcarcinoom
mrt 2024 | Gynaecologische oncologie